Related Experiment Video

Updated: Jan 13, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.5K

CLDN18.2 in Gastric Cancer: Current Therapeutic Landscape and Future Perspectives

Fei Zhang1, Ukyo Okazaki2, Izuma Nakayama3

  • 1Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Journal of Gastric Cancer
|January 10, 2026
PubMed

Insights

Claudin 18.2 is a promising target for advanced gastric cancer. Therapies targeting this protein, like zolbetuximab, are shifting treatment towards a biomarker-driven approach for better outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Claudin 18.2 (CLDN18.2) is a tight junction protein found in normal gastric epithelium.
  • It is frequently retained during gastric carcinogenesis, making it a potential target for cancer therapy.

Purpose of the Study:

  • To review the biological role of CLDN18.2 in gastric epithelium and cancer.
  • To summarize the current and future therapeutic strategies targeting CLDN18.2 in advanced gastric cancer (AGC).

Main Methods:

  • Review of clinical trials (SPOTLIGHT, GLOW) evaluating zolbetuximab, an anti-CLDN18.2 monoclonal antibody.
  • Analysis of the emerging pipeline of CLDN18.2-targeted therapies.

Main Results:

  • Zolbetuximab in combination with chemotherapy established CLDN18.2 as a viable therapeutic target for AGC.
  • A diverse range of CLDN18.2-targeted agents, including mAbs, bispecific antibodies, ADCs, and CAR T cells, are under development.
  • These therapies offer a new, effective treatment avenue for CLDN18.2-expressing AGC.

Conclusions:

  • CLDN18.2-targeted therapy represents a paradigm shift towards biomarker-driven treatment in AGC.
  • CLDN18.2-targeted therapies are expected to become a cornerstone treatment for various stages and types of cancer.
Keywords:
BiomarkerClaudinsGastric cancerTargeted therapy

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.6K
Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K